ROARABLE
Today โŒ˜ Pro Terminal Big Ideas ๐ŸŽฒ Predictions Screener ๐Ÿฆ‹ Butterfly 8 Analysts ๐Ÿ›๏ธ Policy ๐ŸŽฌ Video โ˜… Watchlist ๐ŸŽฒ Prediction Markets ๐Ÿ“Š RQD Track Record ๐Ÿ“… Next Catalysts ๐Ÿ›ก๏ธ Overlap & Crash X-Ray ๐Ÿ“ฐ Live Wire ๐Ÿ‹ 13F Whales ๐Ÿ›๏ธ Congress & CEO Buys ๐Ÿ† $100K Arena โŒ˜ Pro Terminal ๐Ÿ“ Methodology & Corrections
Stock Ratings / Health Care / NVO / options
PFE (73) ABT (77) VRTX (80) BMY (63) โŒ˜ Pro Terminal โ†’

Novo Nordisk A/S (NVO) Options Positioning, Max Pain & Unusual Sweeps

$40.00 +2.20% NYSE โ€ข Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $40.08

Novo Nordisk A/S (NVO) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

๐Ÿ“Š Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) โ†’
ROARABLE D+ โ€ข SELL / AVOID Cap $173.31B
๐Ÿ“ค Share Live RQD Speedometer Card: ๐• Post Reddit StockTwits โฌ‡ Live SVG Card
โšก INSTANT AI QUANT PREVIEW โ€ข $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NVO Below โ€” or Connect Your Own ChatGPT / Claude
๐Ÿค– Mara Quenwick โ€ข AI Quant Lead (Click for Instant Brief) Is NVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
โ–ผ

As of 2026-11-02, Novo Nordisk A/S (NYSE: NVO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $40.00 (+2.20% 1D, market cap $173.31B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, NVO ranks #204 in composite RQD confidence.

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– Ellis Vennor โ€ข AI Peer & Flow Quant (Click for Instant Brief) How does NVO compare to PFE and ABT in the Health Care sector?
โ–ผ

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NVO carries a Roarable D+ (57/100 RQD), trailing P/E of 32.8x, gross margin of โ€”, and ROIC of 9.9%. By comparison, PFE (Pfizer Inc.) holds a B grade (73/100 RQD, P/E 22.0x, ROIC 5.1%, cap $170.71B) and ABT (Abbott Laboratories) posts a B+ grade (77/100 RQD, P/E 27.7x, ROIC 11.9%, cap $180.95B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– Gideon Ashmere โ€ข AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NVO?
โ–ผ

For Novo Nordisk A/S (NVO), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #204 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists โ€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
๐Ÿ›ก๏ธ Portfolio Crash X-Ray
EXT / AFTER-HRS: $40.08 (+0.21%)๐Ÿงฌ Cannibal Buyback (-1.24% YoY Shares)โš™๏ธ Cash Engine: 12/20 (C-) โ€ข 15.8% FCF Margin
Verify 90D Bucket Audit โ†’
๐Ÿ“Š Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY โ€ข 52.2% hit rate โ€” wait for RQD โ‰ฅ 70 breakout).
Audit Bucket Track Record โ†’
RQD QUANT TACHOMETERSELL / AVOID โ€ข D+
025507510057
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0โ€“100 RQD rubric) โ€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ ยท Rk C
Cash (12)Whales (8)SEC (16)Macro (9)CEO (12)
Each axis scored 0โ€“20
12M PRICE TARGET CONE-0.4% Base Target
$67 Bull$40 Base$31 Bear
๐Ÿ“ฌ FREE NVO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: โ€” (No Active Options Snapshot on file for NVO)Realized 20D OHLCV Swing Band: ยฑ3.7%
Deterministic 5-Pillar Attribution (57/100 Composite)
๐Ÿ” WHY NVO SCORES 57/100 (D+) โ€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
โ–ฒ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (28% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) โ€ข Piotroski F-Score 7/9

โ–ฒ #2 Bullish Driver: Cash Engine Quality+12/20 pts (21% of score)

SEC XBRL Trailing 12 Months: 15.8% FCF Margin ($3.83B FCF) & 52% Gross Margin

โ–ผ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

๐Ÿ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 โ†’ Q2 โ†’ Q3 โ†’ Current
Q1 (-3Q)
49
Grade D$38.06+3.4% Next Q
Q2 (-2Q)
52
Grade C-$39.35-1.7% Next Q
Q3 (-1Q)
54
Grade C-$38.67+3.4% Next Q
Current
57
Grade D+$40.00-0.2% Hist 90D ฮฑ
Trajectory: D (49) โ†’ D+ (57)Full Audit โ†’
โš”๏ธ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

โš”๏ธ Adversarial Opposing Case: Why the NVO Bull Thesis Could Fail

Gideon Ashmere Forensic Desk โ†’

Even with a 57/100 (D+) score, NVO faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

โš ๏ธ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

โš ๏ธ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) โ€” any gross margin slip below 49.5% triggers an automatic RQD downgrade.

โš ๏ธ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($40.92) or 200D SMA ($43.98) invalidates the momentum regime and cuts Target Base ($39.82) toward Bear Floor ($31.06).

๐ŸŽฒ LIVE PREDICTION MARKET ODDS TIED TO $NVOโ€ข $2.4M Crowd Pool โ€ข Kalshi / Polymarket Composite
Contract: โ€œNVO Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMAโ€
YES 57%NO 43%Trade / Inspect Odds โ†’
CALL VS. PUT WHALE SHARE
โ€” (No Active Options Snapshot)
Put/Call Ratio: โ€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
โ€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
ยฑ3.7%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (NVO)

โ€” (No Active Options Snapshot) โ€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for NVO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

๐Ÿ† Enter Free $100K Paper Arena โ†’
ON-DEMAND RQD QUANT WORKSHOP โ€ข SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NVO)

  • โœ“Walkthrough of NVO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • โœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • โœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) โ†’$100K Arena
NVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.89%๐Ÿ“ HORIZONTAL RANGE
2026-11-02O $38.29H $40.00L $38.29C $40.00VOL 10.44M
RES: $58.58SUP: $33.75SMA50: $40.92SMA200: $43.98
$53.19$48.76$44.33$39.90$35.48RES $58.58SUP $33.75$40.002026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

๐Ÿฆ‹ NVO Butterfly Map โ†’ + Track NVO โ†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth

vs. +2.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NVO today. View full Setup Ledger โ†’

๐Ÿฆ‹ Documented & Second-Order Butterfly Connections Open Graph โ†’
LLY โ†’ NVO Confirmed Filing
Eli Lilly dual GIP/GLP-1 agonist tirzepatide (Zepbound/Mounjaro) demonstrated superior head-to-head weight loss vs. Novo Nordisk semaglutide (Wegovy) in SURMOUNT-5, intensifying PBM rebate competition.
DHR โ†’ NVO Analyst Hypothesis
Novo Nordisk $6B+ annual API manufacturing expansions utilize downstream purification chromatography resins and single-use filtration consumables where Danaher Cytiva and Pall hold leading bioprocess share.
NVO โ†’ ISRG Confirmed Filing
Intuitive Surgical explicitly disclosed in its Form 10-K that US bariatric surgery procedure volumes on da Vinci robotic systems slowed as patients trialed GLP-1 weight-loss drugs prior to surgery.
AI Analyst Theses, Washington Policy & Company Video
๐ŸŽฌ No recent verified company-specific video clip queued for NVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk โ†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT โ€ข SEC EDGAR XBRL ร— RQD PEER BENCHMARK

๐Ÿ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NVO)

Health Care Rank #204 of 1016 โš”๏ธ PFE vs NVO Full Matrix โ†’

1. Head-to-Head Health Care Peer Comparison (NVO vs. PFE, ABT, VRTX, BMY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Novo Nordisk A/S (NVO) ranks #204 by composite RQD confidence (57/100, grade D+) and #12 by equity capitalization ($173.31B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. VRTX currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with NVO at 57/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NVO ACTIVE
Novo Nordisk A/S
D+ 57/100 32.8x โ€” 9.9% +2.20% $173.31B Benchmark Subject
PFE
Pfizer Inc.
B 73/100 22.0x 74.3% 5.1% +1.90% $170.71B /pfe-vs-nvo โ†’
ABT
Abbott Laboratories
B+ 77/100 27.7x 56.4% 11.9% +1.56% $180.95B /abt-vs-nvo โ†’
VRTX
Vertex Pharmaceuticals Incorporated
B+ 80/100 34.6x 86.2% 20.0% +3.50% $136.87B /vrtx-vs-nvo โ†’
BMY
Bristol-Myers Squibb Company
C 63/100 17.8x 71.1% 13.3% +1.78% $125.40B /bmy-vs-nvo โ†’

2. NVO Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Novo Nordisk A/S (NVO) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $173.31B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of โ€”, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 7/9.

3. NVO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

โœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Novo Nordisk A/S (NYSE: NVO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $40.00 (+2.20% 1D, market cap $173.31B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, NVO ranks #204 in composite RQD confidence.

How does NVO compare to PFE and ABT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NVO carries a Roarable D+ (57/100 RQD), trailing P/E of 32.8x, gross margin of โ€”, and ROIC of 9.9%. By comparison, PFE (Pfizer Inc.) holds a B grade (73/100 RQD, P/E 22.0x, ROIC 5.1%, cap $170.71B) and ABT (Abbott Laboratories) posts a B+ grade (77/100 RQD, P/E 27.7x, ROIC 11.9%, cap $180.95B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NVO?

For Novo Nordisk A/S (NVO), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #204 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NVO trading relative to its 50-day, 200-day, and 52-week technical levels?

NVO last traded at $40.00 (+2.20% on volume of 15,277,524 shares), positioning the stock -2.25% below its 50-day simple moving average ($40.92) and -9.05% below its 200-day simple moving average ($43.98). Across its 52-week range of $35.12 to $64.16, NVO sits at the 16.8% percentile with a 14-day RSI of 47.9 (NEUTRAL RANGE) and an implied next-earnings move of ยฑ3.7% ($38.52 to $41.48).

NVO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS โ€ข SEC EDGAR ร— CBOE ร— FRED

What is NVO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for NVO.

Direct Sub-Reports: NVO RQD Cockpit NVO 12M Forecast NVO Earnings & Move NVO Dividends & DRIP NVO Insiders & 13F NVO Whale Options NVO Profit Sankey NVO News & Why
ROARABLE RATING BRIEF โ€ข RQD 57/100 (D+) โœ“ STAGE-C NUMBER FIREWALL VERIFIED

NVO โ€” Novo Nordisk A/S: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:09:13Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NVO scores 57 out of 100, equating to a letter grade of D+ and the verdict "Roarable Sell โ€” Weak Fundamentals / Trim." The five pillars are:

  • Fundamental Cash Engine (12 / 20): Reflects ROIC of 9.9% and FCF yield of 2.21%. Returns on invested capital are positive but modest, and the cash yield is thin relative to the $173.31B market capitalization, implying the market is pricing in substantial future growth.
  • Whale 13F Flow (8 / 20): Reflects institutional accumulation and options positioning. This is a weak score, suggesting limited evidence of sustained large-holder conviction in the source data.
  • Insider Conviction (12 / 20): Reflects SEC Form 4 and Congressional PTR cluster flow. The score is middling; the source data does not itemize the underlying transactions.
  • Macro Regime Fit (9 / 20): Reflects beta of 0.87 and sector sensitivity. The low beta indicates below-market price sensitivity, but the score is weak, indicating the regime-fit assessment is not favorable.
  • Forensic Balance Sheet (16 / 20): Reflects Altman Z-Score of 3.74, Piotroski F-Score of 7/9, and Debt/Equity of 0.39. This is the strongest pillar and points to a sound balance sheet.

Investor implications: the rating's composite weakness is driven mainly by cash-return metrics, institutional flow, and regime fit, while balance-sheet strength is a genuine offset. Valuation is demanding on the trailing and forward multiples shown below (P/E TTM 32.8, Forward P/E 30.5), so upside depends on earnings growth materializing. The rating does not constitute a recommendation; it is a structured summary of the factors in the source data.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
39.14$173.31B32.830.5211.190%0.87$35.12 - $64.169.9%

Business

Novo Nordisk A/S (NVO) is a NYSE-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. Per the Butterfly Supply-Chain Graph, its GLP-1 franchise represents more than 55% of revenue per the company's Form 20-F disclosure. The source data does not detail customer segments or the specific revenue-generation mechanics beyond the GLP-1 concentration and the references to injectable products (Wegovy) and API manufacturing.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the headlines are predominantly "MARKET WIRE" or "CATALYST" items, with one "RISK WATCH" item:

  • RISK WATCH: A headline reports that the CEO was asked why the stock keeps falling on good news, with the CEO's answer referencing market timing.
  • CATALYST: A headline reports NVO moving down while the broader market gained.
  • MARKET WIRE: Headlines comparing NVO to AbbVie, general trending-stock coverage, and a TradingKey item reporting a 3.38% move on Oct 15.

Per the Butterfly Supply-Chain Graph, the key linked catalysts are:

  • LLY โ†’ NVO (Substitute, Headwind, Confirmed Filing): Eli Lilly's tirzepatide reportedly demonstrated superior head-to-head weight loss versus semaglutide in SURMOUNT-5, intensifying PBM rebate competition. Next catalysts cited are Phase 3 oral orforglipron/retatrutide readouts and Medicare Part D IRA price negotiation updates.
  • DHR โ†’ NVO (Direct Supplier, Tailwind, Analyst Hypothesis): Second-order exposure to bioprocessing chromatography and filtration consumables tied to Novo's API expansions. Exposure percentage is undisclosed. Next catalyst is Danaher's Biotechnology bioprocessing order book-to-bill print.
  • NVO โ†’ ISRG (Potential Loser, Mixed Constraint, Confirmed Filing): Intuitive Surgical's Form 10-K cites a ~3%โ€“4% bariatric procedure mix headwind attributed to GLP-1 use.

No proprietary signals are listed in the graph.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the primary ripple theme is GLP-1 metabolic drugs, fill-finish bottlenecks, and MedTech ripple effects. The graph's supply_chain field is "NONE," so no direct upstream supplier list is provided; the DHR linkage is classified as an analyst hypothesis rather than a confirmed filing.

Items to monitor:

  • Competitive net-price pressure: Per the graph, PBM preferred-formulary access may require steeper gross-to-net rebates as injectable supply normalizes and next-generation candidates advance. This is a margin-side risk.
  • Bioprocessing consumables: Second-order exposure to Danaher's bioprocessing segment, with the competing explanation that a shift from recombinant yeast fermentation toward solid-phase peptide synthesis or oral small molecules would change purification resin intensity per kilogram.
  • MedTech demand substitution: Intuitive Surgical's bariatric procedure volumes are cited as slowed by GLP-1 pre-surgery use, though the graph notes bariatrics is under 5% of global da Vinci procedures and that the drag may be absorbed elsewhere.
  • Sector correlation: The source data does not provide sector correlation coefficients.

Open Questions

  • What are the reported revenue, operating income, net income, EPS, FCF, cash, and debt figures by period? The financials section is empty, so the trend cannot be evaluated directly.
  • What is the analyst consensus rating and price target distribution? The analyst data section is empty.
  • What SEC Form 4, 13F, or Congressional transactions underlie the insider and whale pillar scores? The holders section is empty.
  • Why is gross margin reported as 0%, and what is the true gross margin? The market data value appears to be a data artifact.
  • What is the magnitude of the ISRG bariatric headwind and the DHR consumables exposure in dollar or percentage-of-revenue terms? The graph gives a range for ISRG and no figure for DHR.

NVO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Novo Nordisk A/S (NVO) โ€ข Click "Debate This Headline" to argue it in the Roar Pit below

๐Ÿ’ฌ Jump to NVO Debate Forum (3) โ†“
๐Ÿ”ฅ THE ROAR PIT โ€ข LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NVO Bull vs. Bear Conversation Board โ€” What's Your Call at $40.00?

๐Ÿ‚ 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NVO ๐Ÿป 50% BEARISH CONVICTION
1. Pick Your Side on NVO:
๐Ÿ’ก Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk โš–๏ธ DEBATE HOST ๐ŸŽฏ Target: $42.27 (+8.0%)
๐Ÿ“Œ Pinned Debate

๐Ÿ”ฅ Official Bull vs. Bear Debate: Is NVO (D+ โ€ข RQD 57/100) a Buy at $39.14?

Welcome to the NVO (Novo Nordisk A/S) Roar Pit. Current RQD Composite is 57/100 (Roarable Sell โ€” Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (๐Ÿ‚ Bull or ๐Ÿป Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch ๐Ÿป BEARISH ๐ŸŽฏ Target: $32.09 (-18.0%)
Spot @ $39.14

Pump the brakes on NVO โ€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NVO, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless Novo Nordisk A/S expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader ๐Ÿ‚ BULLISH ๐ŸŽฏ Target: $45.40 (+16.0%)
Spot @ $39.14

NVO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NVO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $39.14 (52-wk range $35.12 - $64.16), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%